Latin America CAR T-Cell Therapy Market (2026-2031)
The Latin America CAR T-Cell Therapy Market was valued at $0 Million in 2026 and projected to reach to $0 Million by 2031, representing a compound annual growth rate of . Latin America's CAR T-cell therapy market currently stands at zero market size in 2026, with no projected growth through 2031, reflecting the region's early developmental stage and significant adoption barriers.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Latin America CAR T-Cell Therapy Market Trends and Insights
- The region faces significant barriers to CAR T-cell adoption, including limited healthcare infrastructure, restricted patient access to advanced immunotherapies, and regulatory challenges that impede market entry for innovative treatments.
- Latin America's market trajectory through 2031 reflects the region's ongoing struggle to integrate cutting-edge cellular therapies into standard oncology practice. Despite global momentum in CAR T-cell therapy, Latin America has not yet established a measurable commercial footprint in this segment.
- The absence of established reimbursement frameworks, limited clinical trial infrastructure, and economic constraints across most Latin American countries continue to restrict market development.
- Latin America's healthcare systems prioritize conventional chemotherapy and targeted therapies over expensive cell-based immunotherapies, positioning the region as a lagging adopter through the 2026–2031 forecast period. Latin America's participation in the global CAR T-cell therapy market remains negligible, with no projected growth expected during the forecast window.
- Stakeholders in Latin America must address foundational healthcare gaps and establish regulatory pathways before meaningful market expansion can occur in this therapeutic category..
Key Market Statistics
- CAGR (2026-2031)
- Market Size, 2026 ~USD 0 Million
- Forecast, 2031 ~USD 0 Million
- Geography Latin America
Latin America CAR T-Cell Therapy Market Overview
Early-Stage Market Development :
Latin America's CAR T-cell therapy market remains in nascent stages with zero market penetration as of 2026, representing a significant gap compared to North American and European markets that have established clinical adoption and reimbursement pathways.
Infrastructure and Access Barriers :
Limited healthcare infrastructure, insufficient specialized oncology centers, and restricted patient access to advanced immunotherapies create substantial obstacles to CAR T-cell therapy adoption across Latin American countries.
Regulatory Challenges :
Complex and fragmented regulatory frameworks across Latin American nations impede market entry for innovative CAR T-cell treatments, delaying approvals and limiting commercial viability for manufacturers.
Future Growth Potential :
Despite current market stagnation, Latin America presents untapped growth opportunities as healthcare systems modernize, regulatory pathways evolve, and regional manufacturing capabilities develop to support immunotherapy accessibility.
Latin America CAR T-Cell Therapy Market Dynamics
- The market faces structural challenges including limited healthcare infrastructure, insufficient access to advanced immunotherapies, and regulatory complexities that prevent meaningful market penetration. However, the region presents substantial long-term potential as healthcare systems strengthen and regulatory frameworks mature.
- Increased investment in oncology infrastructure, growing awareness of precision medicine, and potential regional manufacturing partnerships could catalyze market development beyond 2031.
- Strategic partnerships between global manufacturers and local healthcare providers may accelerate CAR T-cell therapy accessibility in Latin America..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Merck KGaA
- Thermo Fisher Scientific Inc.
- SANOFI
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- Latin America's CAR T-cell therapy market is negligible in 2026 with zero market size and no growth projected through 2031.
- Latin America lacks the healthcare infrastructure, reimbursement systems, and regulatory frameworks necessary to support CAR T-cell therapy adoption.
- Economic constraints and limited access to advanced oncology care position Latin America as a non-participant in the global CAR T-cell market during the forecast period.
- Latin America requires foundational healthcare system improvements and regulatory pathway development before CAR T-cell therapy commercialization can begin.
CAR T-Cell Therapy Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | CD19/20 (Target) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 13.7% from 2026 to 2031 |
| Largest Segment | CD19 (Target) |
| Market Size Base Year (Billions) | ~USD 7.25 (2026) |
| Revenue Forecast (Billions) | ~USD 13.78 (2031) |
| Segments Covered | Product, Target, Indication |
Latin America CAR T-Cell Therapy Market Report Segmentation
3 segment dimensions are covered across the global market.
By Product
- Abecma
- Breyanzi
- Carvykti
- Kymriah
- Other Products
- Tecartus
- Yescarta
By Target
- Bcma
- Cd19
- Cd19/20
- Cd7
- Other Targets
By Indication
- Acute Lymphoblastic Leukemia (All)
- B-Cell Lymphoma (Bcl)
- Multiple Myeloma
- Other Indications
Target Audience
- Pharmaceutical Manufacturers : Need market intelligence to evaluate Latin America as a future expansion territory and develop localized commercialization strategies for CAR T-cell therapies.
- Healthcare System Administrators : Require data on infrastructure requirements and implementation pathways to prepare healthcare systems for eventual CAR T-cell therapy integration and patient access.
- Investment and Private Equity Firms : Seek market analysis to identify investment opportunities in Latin American healthcare infrastructure, biotech partnerships, and emerging immunotherapy companies.
- Regulatory and Policy Consultants : Need comprehensive regulatory landscape assessment to advise clients on compliance requirements and market entry strategies across Latin American jurisdictions.
- Healthcare Technology Providers : Require market insights to develop solutions addressing Latin America's infrastructure gaps and support the eventual scaling of CAR T-cell therapy delivery systems.
Key Companies in the Latin America CAR T-Cell Therapy Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| JOHNSON & JOHNSON | United States | Public Company | Oncology and Immunology (Innovative Medicine),Neuroscience, Cardiovascular & Metabolism, Pulmonary Hypertension, Infectious Diseases,Surgery and Interventional (instrumentation, energy, stapling, wound closure, biosurgery, robotic and digital), |
| GILEAD SCIENCES, INC. | United States | Public Company | HIV portfolio (Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, Yeztugo),Liver disease and other antivirals (Epclusa, Livdelzi, Vemlidy, AmBisome),COVID-19 (Veklury), |
| BRISTOL-MYERS SQUIBB COMPANY | United States | Public Company | Eliquis (anticoagulation),Immuno-oncology (Opdivo, Yervoy, Opdualag, Opdivo Qvantig),Hematology (Revlimid, Pomalyst/Imnovid, Reblozyl, Abecma, Breyanzi), |
| NOVARTIS AG | Switzerland | Public Company | Oncology & Hematology (Kisqali, Tafinlar+Mekinist, Jakavi, Pluvicto, Lutathera, Scemblix, Fabhalta),Immunology & Neuroscience (Cosentyx, Xolair, Ilaris, neurology assets),Cardiovascular, Renal & Metabolic (Entresto, Leqvio, other CVRM), |
| AUTOLUS THERAPEUTICS | United Kingdom | Public Company | CD19 CAR-T franchise (AUCATZYL / obe-cel – oncology),Autoimmune CD19 programs (obe-cel in SLE, MS, lupus nephritis),Next-generation oncology pipeline (AUTO1/22, AUTO8, AUTO6NG), |
| JW (CAYMAN) THERAPEUTICS CO., LTD. | China | Public Company | Commercial and late-stage CAR-T for hematologic malignancies (Carteyva, JWCAR201, JWCAR239),Autoimmune indications (relma-cel for SLE and related programs),Solid tumor pipeline (JWATM204/214/203/213, JWTCR001, JWCAR031), |
| CARSGEN THERAPEUTICS HOLDINGS LIMITED | China | Public Company | Zevor-cel (CT053) – BCMA CAR-T for R/R multiple myeloma,Autologous solid-tumor CAR-T (CT041, CT011, CT071, CT0590/CT0596),Autoimmune and B-cell malignancy pipeline (KJ-C2219, KJ-C2320, KJ-C2529), |
| CARTESIAN THERAPEUTICS, INC. | United States | Public Company | Descartes-08 (autoimmune and rare pediatric indications),Descartes-15 (multiple myeloma),Platform and other mRNA cell therapy programs/services, |
| LYELL IMMUNOPHARMA, INC. | United States | Public Company | Hematologic CAR T programs (ronde-cel and platform),Solid tumor CAR T programs (LYL273 and related),Platform technologies and enabling IP (c-Jun, NR4A3 KO, Epi-R, CD62L enrichment), |
JOHNSON & JOHNSON
Johnson & Johnson is a diversified healthcare company founded in 1886 and headquartered in the United States. With 138,200 employees, it operates as a public company serving global markets.
GILEAD SCIENCES, INC.
Gilead Sciences, Inc. is a United States-based biopharmaceutical company founded in 1987. The public company employs 17,000 people and focuses on developing innovative therapeutics.
BRISTOL-MYERS SQUIBB COMPANY
Bristol-Myers Squibb Company is a pharmaceutical company established in 1887 in the United States. As a public company with 32,500 employees, it develops and manufactures pharmaceutical products.
NOVARTIS AG
Novartis AG is a Swiss multinational pharmaceutical company founded in 1996. The public company employs 75,267 people and operates globally in the healthcare sector.
AUTOLUS THERAPEUTICS
Autolus Therapeutics is a United Kingdom-based biopharmaceutical company founded in 2014. The public company has 753 employees and focuses on cell therapy development.
JW (CAYMAN) THERAPEUTICS CO., LTD.
JW (Cayman) Therapeutics Co., Ltd. is a China-based pharmaceutical company founded in 2016. The public company employs 314 people and operates in the therapeutic development sector.
CARSGEN THERAPEUTICS HOLDINGS LIMITED
Carsgen Therapeutics Holdings Limited is a China-based biopharmaceutical company founded in 2014. The public company has 355 employees and specializes in cell therapy development.
CARTESIAN THERAPEUTICS, INC.
Cartesian Therapeutics, Inc. is a United States-based public biopharmaceutical company with 75 employees. The company specializes in cell therapy and therapeutic development.
LYELL IMMUNOPHARMA, INC.
Lyell Immunopharma, Inc. is a United States-based public immunotherapy company founded in 2018. The company has 161 employees and develops cell-based immunotherapies.
Countries within Latin America - compare and drill down
| Country | 2025 size (native) |
|---|---|
| Brazil | USD Million |
| Rest Of Latin America | USD Million |
Country market size visualization
Reasons to Buy this Report
- Identify Market Entry Opportunities : Understand the current barriers and regulatory landscape to strategically plan market entry or expansion initiatives in Latin America's emerging CAR T-cell therapy sector.
- Competitive Intelligence : Gain insights into the competitive vacuum and early-mover advantages available in Latin America before the market scales, enabling strategic positioning ahead of competitors.
- Infrastructure Development Roadmap : Access detailed analysis of healthcare infrastructure gaps and investment requirements needed to support CAR T-cell therapy adoption across Latin American countries.
- Regulatory Navigation Guide : Obtain comprehensive understanding of fragmented regulatory frameworks across Latin American nations to streamline approval processes and reduce time-to-market.
- Long-Term Growth Forecasting : Leverage forward-looking analysis to anticipate market inflection points and prepare strategic initiatives for capturing growth as Latin America's CAR T-cell market develops.
Frequently asked questions
What is the current size of the CAR T-cell therapy market in Latin America?
Latin America's CAR T-cell therapy market is estimated at zero USD million in 2026, indicating no established commercial market presence in the region.
What is the projected market size for CAR T-cell therapy in Latin America by 2031?
Latin America's CAR T-cell therapy market is forecasted to remain at zero USD million through 2031, with no anticipated growth during the forecast period.
Why is the CAR T-cell therapy market underdeveloped in Latin America?
Latin America lacks adequate healthcare infrastructure, established reimbursement mechanisms, regulatory approval pathways, and economic resources required to support CAR T-cell therapy commercialization and patient access.
What barriers prevent CAR T-cell therapy adoption in Latin America?
Key barriers in Latin America include limited clinical trial capacity, absence of reimbursement frameworks, high treatment costs, regulatory delays, and prioritization of conventional therapies over advanced immunotherapies.
When might CAR T-cell therapy become available in Latin America?
Meaningful CAR T-cell therapy availability in Latin America requires systemic healthcare improvements, regulatory development, and economic investment that extend beyond the 2026–2031 forecast period.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the CAR T-cell therapy market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), United States Food and Drug Administration (US FDA), American Society of Gene & Cell Therapy (ASGCT), European Medicines Agency (EMA), Industry Association of Synthetic Biology (IASB), International Society for Cell & Gene Therapy (ISCT), National Center for Complementary and Integrative Health (NCCIH), BioPharm International, ScienceDirect, News Articles, Journals, Press Releases, Paid Databases, Expert Interviews, and MarketsandMarkets Analysis, among others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information about major players, global product revenues, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data was collected and analyzed to arrive at the overall size of the global CAR T-cell therapy market, which was validated through primary research.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the CAR T-cell therapy market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
CAR T-Cell Therapy Market Size: Bottom-up Approach and Top-down Approach
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
CAR T-cell therapy is a treatment method wherein a patient’s T-cells (a type of immune system cell) undergo modification in a laboratory to target and attack cancer cells effectively. Initially, T-cells are extracted from the patient’s bloodstream. Then the gene for a special receptor that binds to a specific protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is known as a chimeric antigen receptor (CAR). Following this modification process, the CAR T-cells are cultured and multiplied in large quantities. Finally, the amplified CAR T-cells are administered to the patient via infusion. This therapeutic approach is predominantly utilized in the management of specific blood cancers, and ongoing research is exploring its potential applications in treating other forms of cancer. The CAR T-Cell therapy market includes approved and pipeline CAR T-cell products for therapeutic purposes.
Key Stakeholders
- Pharmaceutical Companies
- Biotechnology Companies
- Clinical Research Organizations (CROs)
- Regulatory Authorities
- Healthcare Providers
- Patients and Patient Advocacy Groups
- Investors and Venture Capital Firms
- Research & Development Companies
- Research Laboratories & Academic Institutes.
- Market Research & Consulting Firms
Report Objectives
- To define, describe, and forecast the CAR T-cell therapy market by value for product, target, indication, demographic, end user, and region
- To define, describe, and forecast the CAR T-cell therapy market by volume for the product segment at the global level
- To provide detailed information regarding the major drivers, restraints, opportunities, and challenges, influencing the market growth
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall CAR T-cell therapy market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
- To provide an overview of the market with specialized analysis such as trends/disruptions impacting customers’ business, pricing analysis, value/ supply chain analysis,ecosystem analysis, technology analysis, patent analysis, key conferences & events 2026-2027, regulatory landscape, Porter’s five forces analysis, key stakeholders and buying criteria, and investment and funding scenario
Available customizations:
- With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographic Analysis
- Further breakdown of the Rest of Europe CAR T-cell therapy market, by country
- Further breakdown of the Rest of Asia Pacific CAR T-cell therapy market, by count
Company Information
- Detailed analysis and profiling of additional market players (up to five
Segment Analysis
- Cross-segment analysis
Get the Full CAR T-Cell Therapy Market Report
Full forecast, segment splits, and company analysis for all CAR T-Cell Therapy Market.
- US CAR T-Cell Therapy Market
- Canada CAR T-Cell Therapy Market
- Germany CAR T-Cell Therapy Market
- UK CAR T-Cell Therapy Market
- France CAR T-Cell Therapy Market
- Italy CAR T-Cell Therapy Market
- Spain CAR T-Cell Therapy Market
- China CAR T-Cell Therapy Market
- Japan CAR T-Cell Therapy Market
- India CAR T-Cell Therapy Market
- Australia CAR T-Cell Therapy Market
- South Korea CAR T-Cell Therapy Market
- Brazil CAR T-Cell Therapy Market
- UAE CAR T-Cell Therapy Market
- Rest Of Europe CAR T-Cell Therapy Market
- Rest Of Asia Pacific CAR T-Cell Therapy Market
- Rest Of Latin America CAR T-Cell Therapy Market
- GCC Countries CAR T-Cell Therapy Market
- Rest Of Middle East CAR T-Cell Therapy Market
- Kingdom Of Saudi Arabia CAR T-Cell Therapy Market
- Rest Of GCC Countries CAR T-Cell Therapy Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report